S. 652 · 118th Congress · Health

Safe Step Act

Died in committee1.4k words Introduced Mar 2, 2023 · Latest action Mar 2, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedMar 2, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer.

A request for such an exception to the protocol must be granted if (1) an otherwise required treatment has been ineffective, (2) such treatment is expected to be ineffective and delaying effective treatment would lead to irreversible consequences, (3) such treatment will cause or is likely to cause an adverse reaction to the individual, (4) such treatment is expected to prevent the individual from performing daily activities or occupational responsibilities, (5) the individual is stable based on the prescription drugs already selected, or (6) there are other circumstances as determined by the Employee Benefits Security Administration.

The bill requires a group health plan to implement and make readily available a clear process for an individual to request an exception to the protocol, including required information and criteria for granting an exception. The bill further specifies timelines under which plans must respond to such requests.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 2, 2023

Who lobbies on it

28 organizations · 169 filings · Q1 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. America's Health Insurance Plans Inc (ahip) 8 of 8 quarters
    “H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 - Rep. Carter, Earl - spread-pricing by PBMs for Medicaid H.R. 2880 - Protecting Patients Against PBM Abuses Act - Rep. Carter, Earl - PBM transparency H.R. 4818 - Treat and Reduce Obesity Act - Rep. Wenstrup, Brad - weight loss coverage H.R. 5372 - Expanding…”

    Q4 2024 filing · $11.8M lobbying spend in 2024, all issues

  2. Genentech 8 of 8 quarters
    “340B Program issues and patient access to pharmaceuticals, including related provisions in H.R. 3290, to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program." Legislative issues associated with patient access to treatment, including: the CMMI Most…”

    Q4 2024 filing · $9.1M lobbying spend in 2024, all issues

  3. American Academy of Dermatology Association 8 of 8 quarters
    “Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate…”

    Q4 2024 filing · $2.8M lobbying spend in 2024, all issues

25 more organizations, every filingPROUpgrade

Organizations that named S. 652 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Mar 2, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Mar 2, 2023Introduced in Senate